What is Sudo Biosciences?
Founded in 2020 and headquartered in Menlo Park, California, Sudo Biosciences is a biopharmaceutical company dedicated to advancing novel therapeutic solutions. Operating within a sector characterized by rigorous research and development, Sudo Biosciences aims to address critical unmet medical needs. The company's strategic positioning is further solidified by its recent Series B financing, indicating a transition from early-stage development to a scaling phase, focused on accelerating its pipeline and market penetration.
How much funding has Sudo Biosciences raised?
Sudo Biosciences has raised a total of $184M across 2 funding rounds:
Series A
$37M
Series B
$147M
Series A (2022): $37M, investors not publicly disclosed
Series B (2024): $147M led by Dementia Discovery Fund, Frazier Life Sciences Management, TPG, Surveyor Capital, Eventide Asset Management, Sanofi Ventures, and Enavate Sciences
Key Investors in Sudo Biosciences
Dementia Discovery Fund
The Dementia Discovery Fund (DDF) is a specialized venture capital fund focused exclusively on companies developing novel therapeutics for dementia, including Alzheimer's Disease. Managed by SV Health Investors, DDF invests in and creates biotech companies, leveraging its network to drive innovation in a critical area of unmet medical need.
Frazier Life Sciences Management
Frazier Life Sciences is a prominent investment firm that supports the growth of novel therapeutic companies through both venture and public strategies. With significant capital managed and a history of building successful companies, Frazier Life Sciences provides resources and guidance, contributing to the advancement of biotech innovation.
TPG
TPG is a global investment firm managing alternative assets and supporting business growth across various industries, including private equity and credit. Known for its collaborative approach and sector expertise, TPG identifies opportunities and builds long-term value for its portfolio companies worldwide.
What's next for Sudo Biosciences?
The substantial capital infusion from its Series B round positions Sudo Biosciences for accelerated expansion and the advancement of its drug development programs. This strategic investment is expected to fuel further research, clinical trials, and potential commercialization efforts. The company's ability to attract major backers like Dementia Discovery Fund, Frazier Life Sciences, and TPG signals strong validation of its scientific approach and market potential, paving the way for significant milestones in the biopharmaceutical arena.
See full Sudo Biosciences company page
